? lymphocytes) inhibit an antitumour immune response. Additional studies have also reported that the T reg population increases in peripheral blood and tumour tissues from patients with cancer. However, the relationship between the T reg population and the patient prognosis remains controversial. Our aim was to determine the prognostic value of T reg cell density in breast cancer using immunohistochemical assessment of FOXP3, which has been shown to be the optimal marker for T regs. Tissue microarrays were used, and the density of FOXP3
Introduction
Breast cancer is a heterogeneous disease with different known biological subclasses some of which are associated with immune cell infiltration [1] . The existing literature is not consistent on the importance of inflammatory cell infiltration in breast cancer development [2] . The presence of inflammatory cells may represent an immune response to the tumour, but could also potentially exhibit pro-tumour effects including stimulation of tumour invasion or angiogenesis. Some studies have reported that a dense lymphohistiocytic infiltrate is associated with a favourable prognosis [3, 4] ; however, other reports have shown an association between prominent inflammation and a poor patient outcome [5] . A detailed understanding of the functional peculiarities and phenotype of individual T lymphocyte subtypes may explain this paradox [6] .
An important mechanism of defence against autoimmunity is the central tolerance which involves deletion of self-reactive T lymphocytes in the thymus at an early stage of development [7] . However, autoreactive T cells that migrate into the tumour periphery are controlled by a number of peripheral mechanisms including the induction of regulatory/suppressor T cells [8] . CD4
? T regulatory (T reg) cells include at least four populations that differ in phenotype, cytokine secretion profile, and suppressive mechanisms [9, 10] . One prevailing phenotype is the naturally occurring T reg cells that originate in the thymus and are involved in protection from autoimmune responses. These natural T reg cells have the ability to suppress the activation of conventional T cells in a cell-contact-dependent, IL-10-independent and TGF-b-independent manner [9, 11] .
Naturally occurring CD4 ? T reg cells are characterised by the expression of the IL-2 receptor a-chain (CD25) and constitute 5-10% of peripheral CD4
? in healthy individuals [12] . These cells naturally arise in the thymus and after differentiation, the naïve CD4
? CD25 ? CD45RA ? T cells are exported to the periphery where they suppress the activation of T cells potentially reactive to the self [10] . In addition to CD4 and CD25 markers, T reg also constitutively express CD45RO and CD152 (CTLA-4) [13] . Ex vivo studies on these cells revealed a poorly proliferative cell population that secretes inhibitory cytokines such as TGF-b and IL-10 [12] . They are implicated in many autoimmune diseases such as multiple sclerosis, diabetes, thyroiditis, and inflammatory bowel diseases. Besides their role in autoimmunity, Treg cells participate in transplantation tolerance and tumour immunity [14] .
Although the expression of CD25 on T cells has been described as a marker of T reg cells, its expression is not restricted to T reg cell function as it is also expressed by activated non-regulatory effector lymphocytes [15] . Previous studies revealed that the most specific marker to identify T reg cells is FOXP3, a member of the forkhead or winged helix family of transcription factors encoded on the X chromosome [16, 17] . The nuclear expression of FOXP3 protein is highly restricted to discrete T reg cell populations and it is therefore considered to be a specific marker to detect T reg cells in vivo [17] .
Studies in mice showed that T reg inhibit the antitumour response [18, 19] and that their depletion can result in effective antitumour immune response [20, 21] , implicating these cells in immune evasion by cancer cells. Additional studies have reported that the T reg population increases in peripheral blood and tumour tissues in patients with several types of human cancer including breast cancer [13, [22] [23] [24] . A high density of tumour-infiltrating FOXP3 ? cells has been associated with poor outcome in various solid tumours including ovarian [23] , pancreatic [25] , lung [26] , and hepatocellular carcinoma [27] . In contrast, improved patient survival has been shown to be associated with a high density of tumour infiltrating FOXP3
? T regs in oesophageal squamous cell carcinoma [28] and colorectal cancer [29] .
A few studies have recently examined the role of FOXP3
? cells in breast cancer and have utilised relatively small patient cohorts [22, 30] . In the largest study, Bates et al. [22] studied 222 invasive breast carcinomas and focused on the prognostic value of FOXP3
? cells in ERpositive tumours, while Ladoire et al. [30] concentrated on the pathologic response to neoadjuvant chemotherapy. There is still limited information delineating the mechanisms behind T reg accumulation within the breast cancer microenvironment and their expansion locoregionally. Thus, it is important to evaluate the localisation of infiltrating T regs in relation to clinical outcome. The aim of this study is therefore to determine the prognostic value of FOXP3
? cell density and localisation in a large wellcharacterised series of invasive breast cancer with long follow-up. Furthermore, we have correlated the number of FOXP3
? cells infiltrating breast carcinomas with other recognised prognostic factors.
Patients and methods

Study population
This retrospective study is based on a consecutive unselected series of 1902 patients from the Nottingham Tenovus Primary Breast Carcinoma series who presented during the period 1987-1998. This is a well-characterised series of primary operable invasive breast carcinomas patients less than 71 years of age, treated in a single institution, which has been previously investigated for a wide range of prognostic factors [31] [32] [33] [34] . Data on a range of patient, pathology and biomarkers were available. These include histologic grade [35] , histologic tumour type [36] , vascular invasion (VI) [37] , primary tumour size, and lymph node (LN) stage and Nottingham prognostic index (NPI) [38] , which were routinely assessed and recorded in the database as well as patients' information such as age, family history and menopausal status.
All patients received standard surgical treatment of either mastectomy or wide local excision with radiotherapy. Prior to 1988, patients did not routinely receive systemic adjuvant treatment. From 1988, patients were offered systemic adjuvant treatment based on NPI score and hormone receptor status [39] . Patients with an NPI score B 3.4 received no adjuvant therapy, those with a NPI score [ 3.4 received Tamoxifen if oestrogen receptor (ER) positive (±Zoladex if pre-menopausal) or classical cyclophosphamide, methotrexate and 5-fluorouracil if ER negative and fit enough to tolerate chemotherapy. Information on local, regional and distant recurrence and survival were maintained on a prospective basis. Patients were followed up at 3-month intervals initially, then every 6 months and then annually for a median follow-up period of 128 months (range 4-243). Breast cancer-specific survival (BCSS) was defined as the time (in months) from the date of the primary surgical treatment to the time of death from breast cancer. Patients who died from other causes or were still alive were censored at the time of last follow-up. Disease-free interval (DFI) was calculated from the date of first operation until the first recurrence (local, regional or distant). The number of deaths due to breast cancer was 398, while the number of relapses was 581. The clinicopathological characteristics of the series are presented in Table 1 . Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK) criteria were followed throughout, as recommended by McShane et al. [40] . This study was approved by Nottingham Research Ethics Committee 2 under the title of ''Development of a molecular genetic classification of breast cancer''.
Tissue microarrays and immunohistochemistry
Breast cancer tissue microarrays (TMA) and whole breast cancer tissue sections were prepared and immunohistochemistry performed employing the standard streptavidinbiotin complex method as previously described [41] . In short, tissue sections were deparaffinised with xylene then rehydrated through three changes of alcohol. Endogenous peroxidase activity was blocked by 0.3% hydrogen peroxide for 10 min. Antigen retrieval was performed by microwave treatment in 0.01 M Tris-EDTA buffer (pH 8) for 20 min. Slides were incubated for 1 h with monoclonal mouse anti-human FOXP3 (clone 236A/E7, Abcam, Cambridge, UK, 1:100 dilution). After washing with Tris-buffered saline (TBS, pH 7.6), sections were incubated with biotinylated secondary antibody (1:100 dilution) for 30 min, followed by streptavidin coupled to biotinylated horse radish peroxidase (1:100 dilution) for a further 55 min using streptABC kit (streptABComplex/ HRP Duet, biotinylated goat antimouse/rabbit immunoglobulin kit, Dako Corporation, Denmark, K0492). Antigen-antibody reaction was visualised with 3,3 0 -diaminobenzidine tetrahydrochloride (Dako, K3468). After counterstaining with Mayer's haematoxylin, sections were dehydrated through ascending alcohols to xylene and mounted. Positive staining controls were performed in parallel with paraffin sections of normal human tonsil. Negative control was performed by omitting the primary antibody.
To assess the topographical distribution and heterogeneity of FOXP3
? cell distribution, immunoreactivity was also determined in 30 cases (included in the TMA) using full-face tissue sections.
Quantification of FOXP3
? cells
The number of FOXP3 ? cells was counted in each tumour core (0.6-mm diameter) using an eyepiece graticule. The scorer was blinded to the patients' clinical information (S.M.). Scores were audited by a second assessor (I.O.E) and a very good correlation was found between the two investigators' scores (j value = 0.9). FOXP3
? cells were counted in three compartments in each tumour; intratumoural compartment (within the tumour cell nests); within distant stroma not touching tumour cells (defined as the distance between positive FOXP3 cell and tumour nest is more than the size of one tumour cell); and within adjacent stroma and touching tumour cells (the distance between positive FOXP3 cell and tumour nest is equal or less than the size of one tumour cell) (Fig. 1c, d ). The total number of FOXP3
? cells was determined by adding the counts for the three compartments. ? cells and clinicopathological characteristics was conducted using Spearman rank order correlation or MannWhitney U test where appropriate. Concordance between scores from both observers was obtained using Kappa (j) measure of agreement test. All tests were 2-tailed.
X-tile software program (version 3.4.7, Robert L Camp, 2005) was utilised to define the single optimal cut-off point for FOXP3
? cell count with corrected P value and relative risk against BCSS in each tumour compartment [42] . X-tile software provides a method to determine the optimal divisions of a continuous population and then does statistical testing using training set/validation set method for P value estimation when no foreknowledge about how a marker parses a population into subsets. In addition, the software can perform standard Monte Carlo cross-validation to produce corrected P values to assess statistical significance of data assessed by multiple cut-points [42, 43] .
Survival rates were determined using Kaplan-Meier method and compared by the log-rank test. Multivariate analysis using Cox proportional hazards regression model determined the influence of T regs, when adjusted to other variables, on BCSS. All analyses were conducted using Statistical Package for the Social Sciences (SPSS Inc, version 15, Chicago, IL, USA) software for windows. P value \0.05 was identified as statistically significant.
Cut-off values for ERa, PgR and HER2 included in this study were chosen before statistical analyses as previously described for this patients' series [32, 44] . Basal phenotype positivity was defined as detection of expression in 10% or more of invasive malignant cells for CK5/6 and/or CK14 [33] .
Results
The frequency and localisation pattern of FOXP3 ? cells were distributed mainly in interfollicular (T-cell) areas, although occasionally low numbers of FOXP3
? cells were found within follicles (Fig. 1a, b) . None of the carcinoma cells or mesenchymal cells exhibited staining. A total of 1445 tumours were examined after exclusion of the uninformative cores. FOXP3
? cells were distributed among the three defined tumour compartments with higher numbers of positive cells in the stroma. Figure 1 shows representative photomicrographs of immunohistochemical staining of Treg using FOXP3 antibody. There were more FOXP3
? cells in the distant stroma when compared to FOXP3
? cells within the tumour and adjacent stroma (Table 2) .
Correlation with other prognostic factors
There was a moderate positive correlation between the total number of FOXP3
? cells and tumour grade (Table 1) . Furthermore, there was a significant correlation between total number of FOXP3
? cells and both ER and PgR negativity (Mann-Whitney U test). On the other hand, total number of FOXP3
? cells was positively correlated with HER2 expression and basal phenotype subclasses. FOXP3 expression was weakly inversely correlated with patient age (Table 1) .
Survival analysis
Using X-tile software, the optimal cutpoints identified for positivity and negativity for the total number of FOXP3 In univariate analysis, patients with positive FOXP3 expression, irrespective of locality, had a significantly shorter BCSS than those tumours negative for FOXP3
? cells (P = 0.012, log rank = 6.36, Fig. 2A) , with hazard ratio of 1.32 (95% CI, 1.06-1.63). This effect on survival was most evident during the first 180 months of follow-up. Similarly, an association between intratumoural FOXP3 cell number positivity and shorter BCSS was observed (P = 0.037, log rank = 4.34, Fig. 2B) , with hazard ratio of 1.26 (95% CI 1.01-1.56). Again, the effect on survival was most apparent before 180 months of follow-up. In addition, adjacent stromal FOXP3 cell number positivity was associated with shorter BCSS (P = 0.001, log rank = 10.60, Fig. 2D ), with hazard ratio of 1.39 (95% CI, 1.14-1.70). However, there was no significant difference in survival between patients with positive distant stromal FOXP3 cell numbers and those with negative distant stromal FOXP3 cell numbers (P = 0.235, log rank = 1.41, Fig. 2C ).
In multivariate Cox regression model including well-recognised parameters related to patient outcome (histological grade, tumour size, LN stage, and vascular invasion), total FOXP3 cell number did not retain significance (Table 3) . Likewise, neither intratumoural FOXP3 nor adjacent stromal FOXP3 cell numbers kept significance in the same multivariate model (HR = 0.97, 95% CI 0.78-1.22, P = 0.81; HR = 1.10, 95% CI 0.90-1.36, P = 0.35, respectively).
With regard to DFI, total FOXP3 ? cell number positivity was associated with decline in DFI however that did not reach a significant level (P = 0.068, log rank = 3.33).
Neither intratumoural nor distant stromal FOXP3
? cell numbers had a significant prognostic effect (P = 0.06, log rank = 3.61; P = 0.58, log rank = 0.31, respectively).
Conversely, patients who were positive for adjacent stromal FOXP3
? cell numbers had a significantly reduced DFI (P = 0.013, log rank = 6.23).
Relationship between tumour-cell-associated FOXP3 and patient outcome To further assess the role of FOXP3
? cell localisation in this patient group, we combined intratumoural FOXP3 ? cells and adjacent stromal FOXP3
? cells as inclusive tumour-cell-associated FOXP3
? populations. We defined, using X-tile software, the cut-off value for the new variable as C1 and categorised patients based on this cut-off point into tumour-cell-associated FOXP3
? cell number positive and negative patients. Tumour-cell-associated FOXP3 ? cell number positivity was accompanied with significantly shorter BCSS (P = 0.001, log rank = 10.35, Fig. 3) , with hazard ratio of 1.38 (95% CI 1.13-1.68). In multivariate analysis, after adjustment for histological grade, tumour size, LN stage and vascular invasion, tumour-cell-associated FOXP3
? cell numbers lost significance and was not therefore an independent prognostic factor for patient survival (HR = 1.063, 95% CI 0.865-1.306, P = 0.562). Of note, after exclusion of tumour grade from the multivariate model, tumour-cell-associated FOXP3 expression was an independent predictor of patient survival (HR = 1.27, 95% CI 1.04-1.55, P = 0.019). In the same way, patients with tumours positive for tumour-cell-associated FOXP3
? cells had a significantly shorter DFI (P = 0.003, log rank = 9.01). Nevertheless, which was not significant in multivariate analysis (HR = 1.13, 95% CI 0.95-1.34, P = 0.17).
Survival in oestrogen receptor-positive patients
Bates et al. [22] found that FOXP3
? cells were an independent prognostic factor in patients with ER-positive tumours, but not in patients with ER-negative tumours. We therefore investigated the prognostic significance of T regs in both ER-positive and -negative tumours. Within the ERpositive group total FOXP3
? cell number positivity was significantly associated with shorter BCSS on univariate analysis (P = 0.012, log rank = 6.32, Fig. 4A) , with hazard ratio of 1.39 (95% CI 1.07-1.81), but was not independent of other prognostic factors in multivariate analysis. Also, tumour-cell-associated FOXP3
? cell number positivity was significantly associated with worse outcome in ER-positive patients (P = 0.004, log rank = 8.48, Fig. 4B) , with hazard ratio of 1.45 (95% CI 1.13-1.86), however, was no longer significant in multivariate analysis (data not shown). In contrast, FOXP3
? cell numbers had no significant influence on BCSS within the ER-negative group on univariate analysis (P = 0.79, log rank = 0.07, for total FOXP3 and P = 0.88, log rank = 0.02, for tumour-cellassociated FOXP3, Fig. 4C and D, respectively) .
Prognostic value of FOXP3
? cells in different adjuvant therapy groups
The patients were categorised according to the systemic adjuvant treatment received. The numbers of FOXP3 ? cells were not of prognostic significance in either the group that received chemotherapy (n = 223) or the group that received endocrine therapy (n = 441) on univariate analysis. FOXP3
? cell number positivity was associated with a worse prognosis in univariate analysis of the group not receiving systemic adjuvant treatment (n = 491), but not in multivariate analysis. There were too few patients receiving both the treatments for analysis. No patients received trastuzumab.
Discussion
Naturally occurring T regulatory cells (T regs) have functionally suppressive actions on other effector T cells and have been characterised as a CD4
? CD25 ? population among CD4
? T lymphocytes [12, 45] . Consequently, an inhibitory effect of T regs on anti-tumour immunity has been proposed implicating them in impeding immunosurveillance against cancer [46] . In agreement with this hypothesis, higher numbers of tumour-infiltrating T reg were shown to be associated with poor outcome in pancreatic [25] and hepatocellular [27] carcinomas. In follicular lymphoma, head and neck, and ovarian cancer the number of infiltrating FOXP3
? immune cells has shown to be an independent prognostic factor [47] [48] [49] . However, studies of other tumours have led to conflicting results. No prognostic effect of T reg was observed in a study of anal carcinomas [50] ; whereas in colorectal and oesophageal carcinomas, tumourinfiltrating T reg were associated with favourable prognosis [28, 29] . Limited data are available concerning the effect of T reg infiltration in breast cancer [22, 30, 51, 52] . Furthermore, no data has been previously published on the localisation patterns of FOXP3 ? cells in breast cancer. This study is, to the best of our knowledge, the first report describing the density and localisation of FOXP3
? infiltrating cells in relation to breast prognosis in a large series of patients.
It has been recently reported that FOXP3 is the most reliable marker of T regs [15] . Moreover, it was confirmed that the 236A/E7 antibody clone specifically recognises FOXP3 and not other FOXP proteins [17] . In fact, this clone has been shown the best currently available to study FOXP3 expression by immunohistochemistry [22] . More importantly, although the reactivity spectrum of FOXP3 is composed of T reg and may include small number of CD8 ? cells, it has been recently shown that it is the most accurate single marker of T regs [53] . In this study, we observed FOXP3
? cell infiltration in most of the tumours. Recent studies have reported the expression of FOXP3 mRNA and protein in a limited number of pancreatic carcinoma cells, cell lines [54] and other tumour cell lines of several origins, including breast cancer [55] . In contrast to these studies we did not detect any immunoreactive carcinoma cells in our series. Our data showed significant correlations between T reg infiltration and high tumour grade and ER negativity, consistent with previous reports in breast cancer [22, 52] . In accord with previously published data in breast cancer, we have demonstrated an association between elevated numbers of FOXP3
? infiltrating cells and HER2 positivity. Furthermore, we found a similar relationship in basal phenotype tumours. The association between HER-2 and FOXP3
? cell infiltration can probably be explained by the association of both with histological grade. Eighty-five percent of HER-2 positive tumours were grade 3 and high FOXP3
? cell counts were also associated with higher grade. There is no correlation between HER-2 expression and FOXP3
? cell counts in grade 3 carcinomas (data not shown). By contrast, although 73% of basal carcinomas were grade 3, FOXP3
? cell counts in grade 3 carcinomas were higher in basal tumours. This suggests that factors other than grade are important in the correlation between basal types and FOXP3
? cell counts. We found that higher numbers of FOXP3
? infiltrating cells were associated with a worse prognosis on univariate analysis. This association was found for intratumoural ? cell expression in ER-positive patient outcome. Neither total number nor tumour-cellassociated FOXP3
? cell expression had an impact on BCSS in ER-negative group (C and D, respectively)
FOXP3
? cells and for adjacent stromal FOXP3 ? cells. However, the number of FOXP3
? cells was not identified as an independent prognostic factor in multivariate analysis. This is probably because of the correlation with histological grade, which is a well recognised and powerful prognostic factor in breast cancer. In the only previous prognostic study, Bates et al. [22] , in a much smaller series (222 patients), found that FOXP3
? cell infiltration was associated with a shorter relapse-free survival (P = 0.04) independent of other prognostic factors, but this was not seen for overall survival (P = 0.07).
Bates et al. [22] found that FOXP3 ? infiltrating cells were an independent prognostic factor in patients with ERpositive tumours, but not in patients with ER-negative tumours. We found no such distinction, FOXP3
? cells were not identified as an independent prognostic factor in either group in our series. The number of events (deaths/ relapses) in the ER-positive group was small in the Bates study and their results must be interpreted with caution.
In summary, in this large study, we found that FOXP3
? infiltrating cells in human breast cancer are associated with histological grade, but are not an independent prognostic factor. There are numerous other infiltrating inflammatory cell types observed in breast cancer and the association between T regs and other cells is not clear. Our data suggest that predicting clinical outcome is not possible using T regs alone. We are currently investigating other cell types.
